Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.

# EUCOPE Blog

## Sitemaps

- [XML Sitemap](https://blog.eucope.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Archive](https://blog.eucope.org/archive/)
- [Why Europe Needs a Biotech Act](https://blog.eucope.org/2025/why-europe-needs-a-biotech-act/) - The EU plans a Biotech Act - EUCOPE perspective on needs and opportunities. The Act presents a chance to leverage the EU's ability to reduce fragmentation.
- [Eyes on the Future: Innovating to improve the lives of those living with rare eye diseases this World Sight Day](https://blog.eucope.org/2025/eyes-on-the-future-innovating-to-improve-the-lives-of-those-living-with-rare-eye-diseases-this-world-sight-day/) - In this guest blog post, Sarah Khor of Amgen explains why World Sight Day connects innovation and rare eye diseases with Europe’s competitiveness ambitions.
- [Improving the Paediatric Framework: Aligning Ambition with Reality in the Revision of the General Pharmaceutical Legislation](https://blog.eucope.org/2025/improving-the-paediatric-framework-aligning-ambition-with-reality-in-the-revision-of-the-general-pharmaceutical-legislation/) - This Lab Talk post outlines considerations and recommendations to ensure the revised framework is scientifically sound, operationally feasible, and efficient.
- [The EU’s chance to lead the way on rare diseases: Seizing the opportunity of the WHA Resolution](https://blog.eucope.org/2025/the-eus-chance-to-lead-the-way-on-rare-diseases-seizing-the-opportunity-of-the-wha-resolution/) - In this guest blog post, Sarah Khor, Director at Amgen (EUCOPE member), sets out why the recent WHA Resolution on rare diseases is an opportunity for Europe.
- [Expanding PRIME: Ensuring Faster Access to Orphan Medicinal Products in the EU](https://blog.eucope.org/2025/expanding-prime-ensuring-faster-access-to-orphan-medicinal-products-in-the-eu/) - In this article, Dr Sean Byrne highlight the importance for all OMPs to be be eligible for consideration under the EMA’s PRIME scheme.
- [The importance of achieving a 180-day assessment timeline for medicines](https://blog.eucope.org/2025/the-importance-of-achieving-a-180-day-assessment-timeline-for-medicines/) - In this article, Dr Sean Byrne highlights the benefits of a 180-day assessment timeline for medicines, to patients, innovation and pharmaceutical sector.
- [Vitality of the EU Biotech Sector Depends on a Positive EU Policy Direction](https://blog.eucope.org/2024/vitality-of-the-eu-biotech-sector-depends-on-a-positive-eu-policy-direction/) - The biotech sector has the opportunity to continue to grow, the EU must pursue a positive policy direction sustaining the competitiveness of medical innovation
- [Trans-Atlantic Perspectives on the Future of Pharma](https://blog.eucope.org/2023/trans-atlantic-perspectives-on-the-future-of-pharma/) - Examining current policy initiatives from EU and the U.S. and the implications for the pharmaceutical sector and their standing in a competitive global market.
- [The European Health Data Space (EHDS): Ensuring the digital transformation of healthcare in Europe](https://blog.eucope.org/2023/ehds-the-european-health-data-space-ehds-ensuring-the-digital-transformation-of-healthcare-in-europe/) - In this blog, EUCOPE's Leander Vranken breaks down the barriers that smaller companies face in Europe related to health data and what the EHDS can offer them.
- [The Path to Innovation in Rare Diseases comes through Partnerships –  A reflection on the EU Pharmaceutical Package](https://blog.eucope.org/2023/the-path-to-innovation-in-rare-diseases-comes-through-partnerships/) - Takeda's Toon Digneffe reflects on the EU Pharmaceutical Package focusing on the key issues needed to build a sustainable European rare disease ecosystem.
- [Rare Disease Day 2023: A Shared Vision for the EU Rare Disease Ecosystem](https://blog.eucope.org/2023/rare-disease-day-2023-a-shared-vision-for-the-eu-rare-disease-ecosystem/) - Rare Disease Day 2023 serves as an important reminder of the arduous tasks ahead required to design a brighter future for Europeans living with a rare disease.
- [World Cancer Day 2023: Fostering the EU Advanced Diagnostics Ecosystem to tackle the Cancer Burden](https://blog.eucope.org/2023/world-cancer-day-advanced-diagnostics/) - Every year on 4 February, millions of Europeans combine to raise awareness to fight cancer through early detection, treatment and support.
- [Launch Conditionality: What's at stake?](https://blog.eucope.org/2022/launch-conditionality/) - Alexander Natz breaks down this aspect of the revision of the General Pharmaceutical Legislation and why it would prove unsustainable for smaller companies.
- [The increasing importance of Real World Evidence (RWE) and the need for a multi-stakeholder approach](https://blog.eucope.org/2022/realworldevidence-rwe-multi-stakeholder-approach/) - Real-world evidence (RWE) can complement clinical studies, and in many cases, provide solutions to unanswered questions that will improve our healthcare systems
- [What is Needed to Reinforce Biopharmaceutical Innovation in Europe?](https://blog.eucope.org/2022/what-is-needed-to-reinforce-biopharmaceutical-innovation-in-europe/) - The European Commission’s most fundamental review of the pharmaceutical legislation in decades is actually discouraging innovation and competitiveness.
- [The European Health Data Space (EHDS): How will it impact health technology companies operating in or about to enter the EU?](https://blog.eucope.org/2022/european-health-data-space-impact/) - The EHDS won’t only change how Europeans access and use health data; it’s also hoped that the plan will lead to billions in economic gains for EU life sciences.
- [GUEST: What's on the horizon for life sciences and health care?](https://blog.eucope.org/2022/guest-whats-on-the-horizon-for-life-sciences-and-health-care/) - In this blog, Hogan Lovells remains hopeful that the innovations necessitated by our collective pivot to pandemic life will become a part of our new normal.
- [Five Priorities for a Successful EU HTA Procedure](https://blog.eucope.org/2022/five-priorities-for-a-successful-eu-hta-procedure/) - Our five priorities for a successful EU HTA Procedure aim to prevent further duplication of work, reduce burdens and increase the predictability for all stakeholders.
- [HERA: closer coordination in the EU against COVID-19](https://blog.eucope.org/2021/hera-closer-coordination-in-the-eu-against-covid-19/) - On 27 January, the European Commission launched the consultation on the European Health Emergency Preparedness and Response Authority, HERA for short. The consultation, which main aim is to issue a legislative proposal on the new authority by the end of this year received 154 responses from a wide range of stakeholders. EUCOPE took the opportunity
- [Is it Time for a new Health Paradigm in the EU?](https://blog.eucope.org/2020/is-it-time-for-a-new-health-paradigm-in-the-eu/) - Empowering EMA and ECDC, strengthening EU coordination in case of cross-border health threats EUCOPE read with great interest the European Commission’s proposals to build a European Health Union, and we agree that greater coordination across Member States is very much needed especially during emergency situations. The COVID-19 pandemic has been an economic, social, and health
- [Harnessing Europe’s untapped potential: small and medium pharma](https://blog.eucope.org/2020/harnessing-europes-untapped-potential-small-and-medium-pharma/) - EUCOPE asks the European Commission to put research at the heart of its Pharmaceutical Strategy The European Commission’s Pharmaceutical Strategy for Europe must: Provide ambitious measures to foster research in rare diseases and other disease areas for which we currently have no cure. Harness the potential of small and medium pharmaceutical and medical technology companies.
- [ECRD 2020: OMPs Development in a post-COVID-19 World](https://blog.eucope.org/2020/ecrd-2020-omps-development-in-a-post-covid-19-world/) - The 10th European Conference on Rare Diseases (ECRD), the largest patient-led event on rare diseases and orphan products, presented an excellent opportunity for exchange among the patient community and experts from various backgrounds. Bringing the perspective of OMP focused small to medium companies, EUCOPE held fruitful dialogues with the key stakeholders in the rare space.
- [Rare Disease Day: Celebrating an empowered community](https://blog.eucope.org/2020/rare-disease-day-celebrating-an-empowered-community/) - On Rare Diseases Day, EUCOPE is delighted to host an interview with Laurence Woollard, patient expert and rare disease advocate, to discuss with him the importance of an engaged community and the opportunities and challenges new treatments can bring. Hi Laurence, thank you very much for accepting to meet with us. First of all, can
- [A More Integrated & Collaborative Framework: Our Proposals](https://blog.eucope.org/2019/a-more-integrated-collaborative-framework-our-proposals/) - Science and technology in drug development are changing at a fast pace and bring with them a lot of promises. To cope with this evolution, the regulatory environment will need to adapt if it wants to keep with its mission to best enable the delivery of novel products to patients. Representing small and medium-sized pharmaceuticals
- [Gene & Cell Therapies – Cutting-Edge Technologies within Reach](https://blog.eucope.org/2019/gene-cell-therapies-cutting-edge-technologies-within-reach/) - gene and cell therapies. Cutting-edge technologies within reach. Some key answers to support the development of an appropriate EU framework for these new treatments.
- [Are Solutions for Rare Diseases in Jeopardy?](https://blog.eucope.org/2019/are-solutions-for-rare-diseases-in-jeopardy/) - This blog was originally published in French, in Les Echos newspaper. How can we align the progress of medicine with the patients’ needs? How can we ensure that new life-saving medicines continue to be produced? How can Europe keep its status of a world-leading hub for medical research and innovation? How can we improve prevention?
- [EUCOPE Blog: Let us discuss - send us your stories](https://blog.eucope.org/2019/eucope-blog-let-us-discuss-send-us-your-stories/) - Welcome to our blog. With this platform, EUCOPE wanted to create a space for open conversation, for different opinions, where your stories could find a place. The objective of the blog is to host articles written by authors representing a varied background. We will host patients' stories, opinions from academics, articles from stakeholders, and occasionally
- [Falsified Medicines in the EU: New Features for Better Patient Safety](https://blog.eucope.org/2019/falsified-medicines-in-th-eu/) - As of 9 February 2019, most prescription medicines supplied in the European Union are required to have a unique identifier (a two-dimension barcode) and an anti-tampering device on their outer packaging. These mandatory safety features are implemented through a delegated regulation that comes into application on 9 February 2019. It will apply in all EU/EEA
- [EUCOPE 10-Year Anniversary Event – Thinking Ahead](https://blog.eucope.org/2019/eucope-10-year-anniversary-event-thinking-ahead/) - You couldn’t have thought of a better stage. The Solvay Library, in Brussels, Belgium. Where some time ago, famous science pioneers such as Albert Einstein and Marie Curie gathered up to discuss breakthroughs and discoveries that will shape science and medicine for ever. On the eve of the 8th of October 2018, pharma top execs,
- [Changes in sight for OMPs and biosimilars in Germany?](https://blog.eucope.org/2018/changes-in-sight-for-omps-and-biosimilars-in-germany/) - The German Ministry of Health recently released a draft bill proposal that would introduce significant changes to the legislation on Orphan Medicinal Products (OMPs) and biosimilars in Germany. The bill, which has yet to pass the Cabinet for approval, sets out plans for mandatory registries for OMPs and Marketing Authorisations under conditional approval or exceptional
- [Position Paper on Gene & Cell Therapies – Game-changer solutions ?](https://blog.eucope.org/2018/position-paper-on-gene-cell-therapies-game-changer-solutions/) - Gene & Cell therapies have arrived, and bring with them important challenges. Our Task Force, including some of our members active in gene and cell therapies, have worked on a position paper addressing some important questions raised by these novel techniques. The paper sets out our take on HTA and evidential options Funding solutions Patient

## Pages

- [Front Page](https://blog.eucope.org/) - EUCOPE's LabTalks creates an open space for thoughtful insights, comments and opinions on what's happening within the world of European life sciences.

## Categories

- [Uncategorised](https://blog.eucope.org/category/uncategorised/)

## Tags

- [EUCOPE](https://blog.eucope.org/tag/eucope/)
- [Event](https://blog.eucope.org/tag/event/)
- [SMEs](https://blog.eucope.org/tag/smes/)
- [Biotech](https://blog.eucope.org/tag/biotech/)
- [gene](https://blog.eucope.org/tag/gene/)
- [cell](https://blog.eucope.org/tag/cell/)
- [treatment](https://blog.eucope.org/tag/treatment/)
- [paper](https://blog.eucope.org/tag/paper/)
- [orphan](https://blog.eucope.org/tag/orphan/)
- [biosimilar](https://blog.eucope.org/tag/biosimilar/)
- [pharmacy](https://blog.eucope.org/tag/pharmacy/)
- [registries](https://blog.eucope.org/tag/registries/)
- [medicines](https://blog.eucope.org/tag/medicines/)
- [safety](https://blog.eucope.org/tag/safety/)
- [FMD](https://blog.eucope.org/tag/fmd/)
- [patient](https://blog.eucope.org/tag/patient/)
- [research](https://blog.eucope.org/tag/research/)
- [rare diseases](https://blog.eucope.org/tag/rare-diseases/)
- [regulatory](https://blog.eucope.org/tag/regulatory/)
- [EMA](https://blog.eucope.org/tag/ema/)
- [science](https://blog.eucope.org/tag/science/)
- [OMP](https://blog.eucope.org/tag/omp/)
- [HTA](https://blog.eucope.org/tag/hta/)
- [innovation](https://blog.eucope.org/tag/innovation/)
- [rwe](https://blog.eucope.org/tag/rwe/)
- [cancer](https://blog.eucope.org/tag/cancer/)
- [advanced diagnostics](https://blog.eucope.org/tag/advanced-diagnostics/)
- [genomics](https://blog.eucope.org/tag/genomics/)
- [cancer patients](https://blog.eucope.org/tag/cancer-patients/)
- [digital health](https://blog.eucope.org/tag/digital-health/)
- [ehds](https://blog.eucope.org/tag/ehds/)
- [paediatrics](https://blog.eucope.org/tag/paediatrics/)